News

The Swiss drugmaker signed a collaboration and option agreement, which is subject to customary closing conditions and regulatory approvals. Ionis developed two investigational antisense therapies, dubbed AKCEA-APO(a)-LRx and

Humira is currently approved in the US, the European Union and other markets for arthritis related problems and other indications. The investigational compound PF-06410293, a monoclonal antibody (mAb), met

SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called

Under the terms of the development agreement, PvP will conduct all research and development through phase 1 proof-of-principle studies per a pre-defined development plan. Takeda will fund $35

Meeting minutes received from the FDA’s Division of Anti-Infective Products confirmed key elements of the company’s overall plan for benznidazole, including: The company’s proposed 505(b)(2) approach to demonstrate

Microbion, co-located in Vancouver, BC and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of hard to treat and antibiotic-resistant infections. Microbion's lead compound,

BMS’ immuno-oncology agent Opdivo will now be assessed with Janssen’s Darzalex in multiple myeloma, as well as several solid tumor types including including non-small cell lung cancer, pancreatic cancer,

HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer

APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic